mardi 8 décembre 2015

Onco Actu du 8 décembre 2015

1. Biologie

Loss of enzyme promotes tumor progression in endometrial cancer [MD Anderson Cancer Center]

Genetic mutations differ within a single tumor, study finds [University of Michigan Health System]

2.11 Etiologie - Alimentation

Japan: Ham-giving tradition hit by WHO cancer report [BBC News]

2.6 Etiologie - Environnement

Scientists assembled for Monsanto say herbicide not carcinogenic, disputing WHO report [Reuters]

3.1 Tabac

E-cigarette flavorings have dangerous chemicals [STAT]

E-cigarettes contain flavouring chemical linked to deadly 'popcorn lung' [The Telegraph]

5. Traitements

A dive into patient records uncovers possible connection between cancer treatment, Alzheimer’s [Scope Blog]

A new way to deliver microRNAs for cancer treatment [MIT News]

5.12 Immunothérapies

Novartis says CART study findings bolster 2017 approval case [Reuters]

With SQZ Deal, Roche Finally Dips Its Toes into Cell Therapy [Xconomy]

5.2 Pharma

ARIAD Announces Initiation of OPTIC-2L Randomized Phase 3 Trial of ponatinib vs. nilotinib in Second-Line Patients with Chronic-Phase Chronic Myeloid Leukemia [ARIAD Pharmaceuticals]

Threshold Goes Under the Threshold [In the Pipeline]

5.2.1 Pharma - Partenariats

Celgene in Collaboration with Astrazeneca Announce Initiation of Fusion Clinical Development Program in Immuno-Oncology [Celgene]

5.3 Traitements - FDA, EMA,...

UK Patients With NSCLC to get Early Access to Tagrisso [RAPS]

5.8.2 ASH - Pharma

Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015 [Seattle Genetics]

Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ASH 2015 [Seattle Genetics]

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data Presentations in Patients with Acute Myeloid Leukemia at ASH 2015 [Seattle Genetics]

RATIFYing a novel agent in the treatment of AML: Midostaurin shows efficacy in front-line therapy [The OBR Blog]

Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations [Novartis]

Combination Ibrutinib (IMBRUVICA®) Demonstrates a Strong Response Rate in Treatment-Naive Patients with Follicular Lymphoma [AbbVie]

First Data Unveiled from CALLISTO Program Examining the Use of XARELTO® (rivaroxaban) for Treating Blood Clots in People with Cancer [Johnson & Johnson]

Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product [Novartis]

IMBRUVICA® (Ibrutinib) Phase 3 RAY Data Show Significant Reductions in Disease Progression versus Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma Patients [AbbVie]

5.8.3 ASH - Divers

Penn Study: Mutations in Chronic Lymphocytic Leukemia Suggest Potential New Uses of Existing Cancer Drugs [Penn Medicine]

5.8.4 ASH - CAR T

Juno’s Investigational CAR T Cell Product Candidates JCAR015 and JCAR014 Demonstrate Encouraging Clinical Responses in Patients with B-cell Cancers [Juno Therapeutics]

Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma [Novartis]

Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL [Novartis]

5.8.5 ASH - Myélome multiple

Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA® (pembrolizumab) Combined With Lenalidomide and Dexamethasone [Merck]

Checkpoint Inhibitors in Multiple Myeloma: Knocking at the Door of a Crowded Market [The OBR Blog]

Study of Bortezomib Added to Revlimid® and Dexamethasone Backbone Therapy Presented at ASH [Celgene]

IMiD® Combination Therapies Form Backbone of Multiple Myeloma Research at ASH [Celgene]

ASH 2015: Novel combination approaches for multiple myeloma []

Merck immunotherapy Keytruda shows promise in multiple myeloma trial [Reuters]

6. Lutte contre les cancers

ASCO and ACS Issue New Guideline on Breast Cancer Survivorship Care [ASCO]

Organizations issue joint guidelines for breast cancer survivors [Reuters]

6.6 Publications

Research Funders and ORCID: New members, mandates, and platforms [ORCID]

The Importance of Opt-In [ORCID]

6.7 DMP, Big Data & applis

Brigham and Women's blames budget woes on electronic records [STAT]